Ganoderma lucidum and Atherosclerosis Prevention

Reishi and Cardiovascular Health

4 anti-atherosclerosis pathways studied

In high-fat diet rabbit models, Reishi triterpenoids and polysaccharides significantly reduced atherosclerotic plaque area and improved lipid profiles through dual mechanisms.

Li et al., Food & Function, 2021

1990

year of the landmark Reishi platelet inhibition study

35+ years

of cardiovascular Reishi research

No trials

have tested Reishi directly on human plaque progression

Li et al., Food & Function, 2021

View as image ↗

A 2024 review in Heliyon by Ma and colleagues mapped exactly how Ganoderma lucidum polysaccharides interfere with atherosclerosis at the molecular level, identifying three distinct pathways that work on the oxidative, inflammatory, and cholesterol-transport biology of arterial plaque.^[9] Add the platelet aggregation data stretching back to a 1990 landmark study, and Reishi has four documented mechanisms that target the biology of arterial plaque formation.

None of this has been tested in a clinical trial specifically measuring plaque in human arteries. That is the most important thing to say at the outset, because the mechanistic case is genuinely compelling and the honest framing is what sets this article apart from supplement-brand content: the preclinical science is real and interesting, and the human evidence for Reishi and atherosclerosis prevention specifically does not exist yet.

This article covers ganoderma lucidum atherosclerosis research in full: what the mechanisms are, where the animal evidence stands, and exactly where the knowledge ends.

For the broader research picture on Reishi and heart health, the complete Reishi mushroom guide is the starting point.

What Atherosclerosis Is, and Why Reishi's Compounds Target It From Multiple Angles

Atherosclerosis is the buildup of plaques inside arterial walls. Three processes drive it: oxidation of LDL particles (which makes them inflammatory and sticky), chronic low-grade inflammation in the arterial wall, and accumulation of cholesterol that the cells cannot remove fast enough.

Plaque formation begins when oxidized LDL particles are taken up by immune cells called macrophages inside the arterial wall. The macrophages become laden with cholesterol and transform into foam cells, which form the fatty core of plaques. Inflammatory signals then drive further immune cell recruitment, wall thickening, and eventual plaque instability.

Reishi's active compounds happen to target all three drivers. Polysaccharides activate antioxidant pathways that reduce LDL oxidation. Triterpenes suppress inflammatory cytokines via NF-κB inhibition. And specific compounds appear to enhance reverse cholesterol transport, the process by which cells offload cholesterol back into circulation for liver clearance.

This multi-target profile is why researchers have continued investigating Reishi for atherosclerosis for more than three decades, even as clinical trial results in other cardiovascular endpoints (cholesterol, blood pressure) have been mixed. The mechanism fit is too specific to dismiss.

The Four Pathways: How Reishi Targets the Biology of Arterial Plaque

The 2024 Ma et al. review in Heliyon is the most comprehensive dedicated analysis of Ganoderma lucidum polysaccharide (GLP) and atherosclerosis to date.^[9] It identifies three molecular mechanisms for GLP specifically, and the platelet aggregation evidence from other work adds a fourth.

How Ganoderma lucidum targets atherosclerosis (preclinical models)

1. Nrf2/HO-1 pathway activation: Reishi polysaccharides stimulate Nrf2 (a master regulator of antioxidant gene expression) and its downstream enzyme HO-1, reducing oxidative stress in arterial endothelial cells. This suppresses the oxidative modification of LDL particles that initiates plaque formation.

2. TLR4/MyD88/NF-κB inhibition: Reishi polysaccharides inhibit a signaling cascade (TLR4 to MyD88 to NF-κB) that drives production of pro-inflammatory cytokines including TNF-alpha and IL-1 beta. These cytokines amplify arterial wall inflammation and destabilize existing plaques.

3. LXRα-ABCA1/ABCG1 activation: Reishi polysaccharides activate liver X receptor alpha (LXRα), which upregulates the transporters ABCA1 and ABCG1. These transporters move excess cholesterol out of macrophages and foam cells, reducing cholesterol accumulation inside arterial plaques.

4. Platelet aggregation inhibition: Reishi extracts inhibit platelet activation, which is a key driver of thrombotic events that can rupture unstable plaques and trigger heart attacks.

These are the mechanisms that make Reishi a scientifically credible candidate for anti-atherosclerosis research. They are also, at this point, exclusively preclinical. The pathway evidence comes from cell cultures and animal models, not from human arterial imaging studies.

Blocking Oxidized LDL and Arterial Inflammation: The Root-Cause Evidence

Oxidized LDL modification and chronic arterial inflammation are the two root processes of atherosclerotic plaque formation, and both appear in Reishi's preclinical data.

Rahman and colleagues tested Reishi hot water extract at 200 mg/kg in animal models and found significant reductions in total cholesterol, LDL, and triglycerides, alongside HDL increases.^[5] The mechanism they identified was polysaccharide-mediated antioxidant activity that reduced oxidative LDL modification. The significance of this is specific: it's not just that cholesterol levels fell, it's that the form of LDL most dangerous to arteries (the oxidized form) was reduced.

The inflammatory pathway evidence comes from two Bhardwaj et al. studies. The 2014 review documented Reishi's suppression of TNF-alpha, IL-1 beta, and IL-6 via NF-κB inhibition across multiple model systems.^[3] The 2016 animal study confirmed NF-κB pathway inhibition in a different inflammatory model, validating the mechanism rather than just describing it.^[4] The same cytokines (TNF-alpha and IL-1 beta) implicated in those studies are the ones that destabilize atherosclerotic plaques, making the mechanism directly relevant to arterial health.

Chan and colleagues' 2021 comprehensive review of Reishi's cardiovascular effects noted that these anti-inflammatory properties operate through several redundant pathways, making it less likely to be a single-compound effect and more likely to reflect the whole extract's activity.^[7]

The Platelet Problem: 35 Years of Thrombosis Research Starting in 1990

Arterial plaques cause most of their damage when they rupture. The resulting thrombosis, triggered by platelet activation at the rupture site, is what converts an unstable plaque into a heart attack or stroke. Reishi's antiplatelet data addresses exactly this endpoint.

The landmark study is from 1990. Li and Wang demonstrated that Ganoderma lucidum inhibited platelet aggregation in both animal experiments and a controlled clinical study, establishing the basic finding that has been replicated in various forms since.^[1] This was the first clinical evidence of cardiovascular activity from Reishi, and it appeared in a research context when atherosclerosis was increasingly understood as a thrombotic disease.

Thirty years later, Poniedziałek and colleagues ran an in vitro screen of eight edible mushroom species on human platelet aggregation.^[6] Ganoderma lucidum was among the most active species in inhibiting platelet aggregation in that panel. The same team noted an important caveat: at 1.5g/day for four weeks in humans, no noticeable effect on hemostasis was observed. This in vitro/in vivo discrepancy is worth noting directly, because it illustrates the limits of extrapolating cell-culture data to clinical doses.

The antiplatelet finding is mechanistically important for atherosclerosis prevention because it targets the event that turns stable plaque into acute cardiovascular events, rather than just slowing plaque formation.

Reishi in Rabbit Models: The Best Animal Evidence for Plaque Reduction

The most direct animal evidence for atherosclerosis prevention comes from Li and colleagues in 2021.^[8]

In high-fat diet rabbits (a standard model for atherosclerosis induction), combined Reishi triterpenoids and polysaccharides significantly reduced atherosclerotic plaque area in arterial tissue. The lipid panel improved: total cholesterol, LDL, and triglycerides fell, and HDL rose. The team identified a dual mechanism: polysaccharides improved reverse cholesterol transport (moving cholesterol out of plaque-forming macrophages), while triterpenes inhibited cholesterol synthesis.

This is notable because it's not just a lipid panel improvement, it's an actual plaque measurement. Arterial tissue was examined directly. The plaque reduction was significant.

The limitation is that high-fat diet rabbit models accelerate atherosclerosis at a rate and severity rarely seen in humans, making extrapolation difficult. The dose and formulation used in this study would also need to be characterized in terms of human-equivalent amounts.

This study is the closest thing to direct plaque evidence in the Reishi literature. No equivalent measurement exists in human subjects.

Ganoderic Acid A and the Statin-Like Mechanism

A 2025 review by Sui and colleagues provides the most precise mechanistic account of how Reishi's primary triterpene, ganoderic acid A, affects cholesterol synthesis.^[10]

Ganoderic acid A inhibits HMG-CoA reductase via competitive binding. HMG-CoA reductase is the rate-limiting enzyme in the liver's cholesterol synthesis pathway, and it is the same enzyme that statins target. Molecular docking analysis confirmed the binding interaction. This makes ganoderic acid A, mechanistically, a naturally occurring compound with a statin-like target.

The important editorial frame here: this is molecular docking data. The fact that a compound docks to an enzyme in a computer model, or shows inhibitory activity in isolated enzyme assays, does not mean it produces statin-like cholesterol reductions in humans. Oral bioavailability, metabolic processing, and dose-response questions remain.

What it does mean is that the mechanism is specific and structurally based rather than vague. This is not a situation where researchers are extrapolating a general antioxidant effect. It is a documented molecular interaction with a known therapeutic target.

A 2012 controlled human intervention by Chu and colleagues found cardioprotective effects including improvements in antioxidant status and some lipid markers with Ganoderma lucidum supplementation.^[2] This is one of the few controlled human studies showing any positive cardiovascular signal, and it supports (though does not prove) the mechanistic picture outlined above. The limitations (sample size, population specificity) apply.

The full evidence on Reishi and cholesterol, including the human trial data and the honest assessment of whether the animal evidence translates, is covered in the Reishi and cholesterol article.

What Human Evidence Exists on Reishi and Arterial Plaque

The answer is straightforward: no clinical trial has directly measured Reishi's effect on atherosclerotic plaque in human arteries. No arterial imaging studies. No carotid intima-media thickness measurements. No coronary CT angiography trials. The human evidence gap for plaque specifically is complete.

What does exist in human research is evidence on the cardiovascular risk factors that feed into atherosclerosis: LDL cholesterol, blood pressure, inflammatory markers, and antioxidant capacity. That evidence, covered in depth in the Reishi and heart health overview, shows mixed results. The most comprehensive clinical analysis to date, a GRADE-assessed meta-analysis, found significant effects on antioxidant markers but no significant effects on blood pressure or lipid profiles in humans.

The question for atherosclerosis specifically is whether the preclinical mechanisms identified in Ma 2024, Li 2021, and Sui 2025 will translate to clinical plaque regression or prevention in humans. The mechanism case is strong enough to justify clinical trials. Those trials have not been done.

This creates an honest framing challenge: the biology is compelling, the animal evidence is real, and the human evidence is absent. Supplement content that extrapolates from mechanism to clinical recommendation is doing readers a disservice. The preclinical findings are worth knowing and understanding. They are not clinical evidence of benefit.

For a cross-species perspective on how mushrooms in general target atherosclerosis preclinically, the mushrooms and atherosclerosis prevention article situates Reishi within the broader anti-plaque research landscape.

The ergothioneine and atherosclerosis prevention article is a related cross-link: Reishi contains ergothioneine, and the ergothioneine-specific atherosclerosis data adds a fifth mechanistic angle on how Reishi extracts may reduce plaque-forming oxidative stress.

The Bottom Line

Ganoderma lucidum has four documented mechanisms of potential relevance to atherosclerosis prevention: polysaccharide-mediated oxidative stress reduction via Nrf2/HO-1, inflammatory cytokine suppression via NF-κB inhibition, reverse cholesterol transport via LXRα-ABCA1/ABCG1, and platelet aggregation inhibition shown since 1990. Animal model data, including direct plaque measurement in high-fat diet rabbits (Li 2021), supports the mechanistic case. Ganoderic acid A, Reishi's primary triterpene, inhibits HMG-CoA reductase at the same molecular target as statins. No human clinical trial has directly tested Reishi's effect on arterial plaque progression; all evidence remains preclinical.

Frequently Asked Questions

Can Ganoderma lucidum prevent atherosclerosis?

Preclinical evidence suggests Ganoderma lucidum can reduce atherosclerosis markers in animal models. A 2021 study found significant plaque area reduction in high-fat diet rabbits. A 2024 review documented three molecular mechanisms by which Reishi polysaccharides target plaque formation. No human clinical trial has directly tested whether Reishi prevents or slows atherosclerosis in human arteries.

How does Reishi reduce plaque buildup in arteries?

Research identifies four mechanisms. First, Reishi polysaccharides activate the Nrf2/HO-1 pathway, reducing the oxidative modification of LDL particles that initiates plaque formation. Second, they suppress NF-κB inflammatory signaling, reducing the chronic arterial inflammation that drives plaque progression. Third, LXRα activation promotes reverse cholesterol transport, clearing cholesterol from macrophages inside plaques. Fourth, Reishi inhibits platelet aggregation, reducing the clotting events that make unstable plaques dangerous. All four mechanisms are from preclinical research.

What is the mechanism of Ganoderma against atherosclerosis?

The primary mechanisms are: antioxidant activity that prevents LDL oxidation (via Nrf2/HO-1); anti-inflammatory activity that reduces TNF-alpha and IL-1 beta production (via NF-κB inhibition); reverse cholesterol transport that removes cholesterol from artery walls (via LXRα-ABCA1); and antiplatelet activity that reduces thrombotic risk. Ganoderic acid A, Reishi's main triterpene, also inhibits HMG-CoA reductase, the enzyme that controls liver cholesterol synthesis.

Does Reishi reduce inflammation in arteries?

In preclinical models, yes. Reishi extracts suppress production of TNF-alpha, IL-1 beta, and IL-6 through NF-κB pathway inhibition. These are the same inflammatory signals implicated in atherosclerotic plaque instability. The Bhardwaj 2014 review and 2016 animal study both confirmed this anti-inflammatory activity. Whether this translates to reduced arterial inflammation in humans has not been tested directly.

Can medicinal mushrooms reverse or slow atherosclerosis?

Animal models suggest some medicinal mushrooms, including Reishi and others, can reduce plaque formation and improve lipid markers under controlled conditions. Whether they can reverse established atherosclerosis in humans is not established. No clinical trial has measured arterial plaque regression in people taking any medicinal mushroom. The evidence base for mushrooms and atherosclerosis is mechanistically promising but clinically untested.

Sources & References

1. 1. Source details for this reference are not yet available.
2. 2RTHM-00247·Chu, Tanya T W et al. (2012). “Study of potential cardioprotective effects of Ganoderma lucidum (Lingzhi): results of a controlled human intervention trial..” The British journal of nutrition.Study breakdown →PubMed →↩
3. 3RTHM-00578·Bhardwaj, Neha et al. (2014). “Suppression of inflammatory and allergic responses by pharmacologically potent fungus Ganoderma lucidum..” Recent patents on inflammation & allergy drug discovery.Study breakdown →PubMed →↩
4. 4. Source details for this reference are not yet available.
5. 5RTHM-00997·Rahman, Mohammad Azizur et al. (2018). “Evaluation of the Antioxidative and Hypo-cholesterolemic Effects of Lingzhi or Reishi Medicinal Mushroom, Ganoderma lucidum (Agaricomycetes), in Ameliorating Cardiovascular Disease..” International journal of medicinal mushrooms.Study breakdown →PubMed →↩
6. 6RTHM-01114·Poniedziałek, Barbara et al. (2019). “The Effect of Mushroom Extracts on Human Platelet and Blood Coagulation: In vitro Screening of Eight Edible Species..” Nutrients.Study breakdown →PubMed →↩
7. 7RTHM-01332·Chan, Sze Wa et al. (2021). “The beneficial effects of Ganoderma lucidum on cardiovascular and metabolic disease risk..” Pharmaceutical biology.Study breakdown →PubMed →↩
8. 8RTHM-01387·Li, Yanhong et al. (2021). “Ganoderma lucidum triterpenoids and polysaccharides attenuate atherosclerotic plaque in high-fat diet rabbits..” Nutrition.Study breakdown →PubMed →↩
9. 9RTHM-01944·Ma, YiZheng et al. (2024). “Research progress of Ganoderma lucidum polysaccharide in prevention and treatment of Atherosclerosis..” Heliyon.Study breakdown →PubMed →↩
10. 10RTHM-02188·Sui, Qi et al. (2025). “Ganoderic acid A: an in-depth review of pharmacological effects and molecular docking analysis..” Journal of ethnopharmacology.Study breakdown →PubMed →↩